Sorrento Therapeutics (NASDAQ:SRNE) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE) in a research report sent to investors on Thursday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Sorrento Therapeutics Stock Performance

SRNE opened at $0.00 on Thursday. Sorrento Therapeutics has a 1 year low of $0.00 and a 1 year high of $0.03.

About Sorrento Therapeutics

Sorrento Therapeutics, Inc, a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system.